This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Clinic Dermatitis Therapy 
Dermatology Times
DECEMBER 10, 2024
Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.
36 
First Derm
FEBRUARY 21, 2024
Treatment Approaches Vary : Treatment for eczema includes emollients and topical steroids, while psoriasis may be treated with light therapy, systemic medications, and biologics, emphasizing the need for personalized care. Contact dermatitis from metals, latex, chemicals. 2] Why is Eczema Considered a Chronic Condition?
59 
Dermatology Times
OCTOBER 27, 2024
At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.
53 
Dermatology Times
DECEMBER 7, 2023
A patient returns to your clinic seeking systemic therapy for her AD while postpartum and breastfeeding. Test your knowledge on injectables.
73 
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago.
77 
First Derm
JUNE 10, 2024
Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.
45 
The Dermatology Digest
FEBRUARY 14, 2024
Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024. “The
78 Dermatology Times
JULY 13, 2024
A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.
57 
The Dermatology Digest
DECEMBER 13, 2024
Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.
69 
The Dermatology Digest
DECEMBER 11, 2024
Im really excited about the clinical possibilities of this research, says senior author Daniel Kaplan, MD, PhD, Professor of Dermatology and Immunology at the University of Pittsburgh in Pittsburgh, PA, in a news release. There are no good therapies for flushing, so this is a significant unmet need.
41 
The Dermatology Digest
APRIL 10, 2024
Sitryx Therapeutics plans to advance SYX-5219, an oral, targeted, disease-modifying anti-inflammatory therapy that targets pyruvate kinase M2 (PKM2), to the clinic. SYX-5219 will be Sitryx’s first candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a clinical trial authorization (CTA).
36 
The Dermatology Digest
FEBRUARY 8, 2024
This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We And the Skin Disease of the Year Is….
78 
The Dermatology Digest
FEBRUARY 26, 2024
2 In this review, we highlight the “epithelial barrier hypothesis” proposed by Akdis, discuss the important roles of the skin, gut, and respiratory barriers, and discuss novel therapies. Impairment in tight junction expression has been shown to contribute to the barrier dysfunction observed in patients with atopic dermatitis.
74 
Dermatology Times
DECEMBER 3, 2024
Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.
41 
First Derm
DECEMBER 4, 2023
Dry skin is a very common problem in people with atopic dermatitis, a chronic inflammatory skin condition characterized by patches of itchy, dry, red, and inflamed skin. Atopic dermatitis (eczema) characterized by itchy patches of red, inflamed, dry skin. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis.
92 
First Derm
MARCH 22, 2024
Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.
52 
The Dermatology Digest
MARCH 11, 2024
Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.
69 
The Dermatology Digest
MAY 2, 2024
Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.
The Dermatology Digest
JUNE 26, 2024
chief of NIAID’s Laboratory of Clinical Immunology & Microbiology Epithelial Research Unit, found specific strains of R. mucosa in the laboratory, conducted preclinical (laboratory/animal) and clinical (human) studies, and made the bacteria available for commercial, non-therapeutic development. mucosa therapy.
74 
Alison Bladh
JANUARY 1, 2025
Skin Conditions Conditions like eczema, psoriasis, or seborrheic dermatitis can irritate the skin around the brows, leading to hair loss. Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Dermatologic Therapy.
52 
The Dermatology Digest
JANUARY 13, 2025
Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.
36 
The Dermatology Digest
JUNE 14, 2024
The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.
36 
The Dermatology Digest
FEBRUARY 1, 2024
Atopy patch tests (APTs) may be the best way to detect food‐triggered atopic dermatitis (AD), according to a new literature review in Clinical Reviews in Allergy & Immunology. APTs detect sensitization to food proteins responsible for systemic contact dermatitis (SCD), which can then be confirmed by oral food challenge.
36 
The Dermatology Digest
DECEMBER 19, 2023
Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The open-label, single-center Phase 2 clinical trial of ADX-629 included eight mild-to-moderate AD patients.
36 
The Dermatology Digest
FEBRUARY 16, 2024
for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. In addition to CSU, dupilumab is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and prurigo nodularis.
The Dermatology Digest
MARCH 9, 2024
Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?
36 
The Dermatology Digest
MARCH 9, 2024
Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?
36 
Aesthetics Advisor
OCTOBER 3, 2023
Doctors were confronted with a problem: some people simply didn't respond to the investigational treatment, which was offered after standard therapy failed. Strategies to enhance natural killer cell survival and function are needed to improve clinical efficacy. Without treatment, which is simply providing niacin, pellegra can be fatal.
36 
The Dermatology Digest
JUNE 14, 2024
Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.
36 
The Dermatology Digest
OCTOBER 26, 2024
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.
36 
First Derm
JULY 2, 2024
Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.
45 
The Dermatology Digest
JULY 10, 2024
for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.
36 
First Derm
APRIL 5, 2024
Ensuring adherence to therapies in dermatology is paramount for enhancing treatment efficacy and promoting patient well-being. Side Effects of Topical Treatments: Topical acne therapies may be discontinued or used incorrectly due to side effects like erythema, irritation, itching, and desquamation, reducing their therapeutic efficacy.
45 
Aesthetics Advisor
MARCH 10, 2024
In a few studies of children with seborrheic dermatitis, topical borage oil improved the symptoms within 1-3 weeks [ 27 , 28 , 29 ]. In children with eczema (atopic dermatitis), wearing undershirts coated with borage oil for 2 weeks improved their skin barriers. They also had relief from itch [ 30 ].
36 
The Dermatology Digest
MARCH 11, 2024
Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.
36 
The Dermatology Digest
DECEMBER 18, 2023
Air pollution may contribute to the development or worsening of skin conditions such as atopic dermatitis and eczema, according to researchers out of Massachusetts General Hospital (MGH). Carbon monoxide concentrations that were an average of 0.22 ppm in the months of May–September in 2019–2022 rose to 0.6 ppm in July of 2023.
36 
The Dermatology Digest
MARCH 5, 2024
APG777 is the first clinical-stage product candidate from the company’s strategic collaboration with Paragon Therapeutics, Inc. Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
36 
The Dermatology Digest
OCTOBER 24, 2024
APG777 continues to show promise in atopic dermatitis (AD), according to early data. Apogee Therapeutics, Inc. APG777 is a novel half-life extended anti-interleukin (IL)-13 antibody under development for the treatment for AD and other inflammatory diseases.
The Dermatology Digest
MARCH 10, 2024
Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, shares pearls on keeping pediatric patients comfortable during common dermatologic procedures. From distraction techniques to pharmacologic measures, Peter A.
36 
The Dermatology Digest
MARCH 9, 2024
Mark Lebwohl, MD, Dean for Clinical Therapeutics and Waldman Professor and Chairman of the Kimberly and Eric J. Mark Lebwohl, MD, Dean for Clinical Therapeutics and Waldman Professor and Chairman of the Kimberly and Eric J. The biosimilars are here with even more coming down the pike.
36 
The Dermatology Digest
MARCH 9, 2024
Watch Now Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now Biosimilars in Dermatology: Where Do They Fit in?
36 
The Dermatology Digest
DECEMBER 18, 2023
New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It
36 
The Dermatology Digest
MARCH 9, 2024
Watch Now Welcome to the Golden Age of Pediatric Dermatology Elizabeth Swanson, MD Elizabeth (Lisa) Swanson, MD, a pediatric dermatologist in Boise, ID, discusses advances in treating kids with atopic dermatitis, psoriasis, vitiligo, alopecia areata, and hemangiomas. Watch Now Biosimilars in Dermatology: Where Do They Fit in?
36 
The Dermatology Digest
MARCH 11, 2024
In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.
36
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content